Skip to content

CSF neuroinflammatory biomarkers are associated with amyloid-β42/40, tau pathology, and cognitive impairment across the Alzheimer’s disease spectrum

Sep 2026 · Immunologic research · Vol 74 · 0 citations · 89 references
Medicine

TL;DR

Higher CSF neuroinflammatory biomarkers may be linked to AD pathology and cognitive impairment; however, given the observational design, causality cannot be established, and longitudinal mechanistic studies are needed to validate these findings.

View source

Similar papers

Open access Aug 2026

CSF complement proteins are associated with early tau pathology and synaptic damage in an asymptomatic population at risk of Alzheimer’s disease

Findings identify complement dysregulation, especially involving C1q, as an early correlate of tau-linked synaptic pathology, and support a role for complement activation in the AD molecular cascade.

J. Loncke, M. Savard, C. Picard et al. · 0 citations
Open access Sep 2026

Age-dependent associations of peripheral inflammatory biomarkers with cognition and brain structural abnormalities in patients with Alzheimer’s disease and Alzheimer’s disease-related mild cognitive impairment

Background Alzheimer’s disease (AD) is one of the most prevalent neurodegenerative conditions. Chronic peripheral inflammation has been implicated in the pathophysiology of AD. Given their accessibility and cost-effectiveness, peripheral inflammatory biomarkers hold promise as potential indicators for AD. However, thei...

Yi-Da Wang, Min Cheng, Zun-Jing Liu · 0 citations
Open access Sep 2026

Neutrophil-to-lymphocyte ratio predicts early cognitive decline associated with tau pathology in Alzheimer’s disease: a longitudinal study of the ADNI cohort

Elevated NLR was significantly and independently associated with accelerated decline across multiple cognitive domains and an increased risk of clinical progression in older adults at risk for AD and a potential role for peripheral immune dysregulation in early disease trajectories is observed.

Xin Wang, Xiao-Lei Liu, Zhi-Gang Wang et al. · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Aug 2026

A cerebrospinal fluid blood–brain barrier dysfunction score is associated with progression from mild cognitive impairment to Alzheimer's disease

A BBB permeability-related score is associated with longitudinal progression from mild cognitive impairment to clinically diagnosed AD dementia; CD226 is a biologically supported candidate signal; GFRα-1 is hypothesis-generating pending replication.

Jing Yang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.